SNOWBIRD, Utah--(BUSINESS WIRE)--Seventy percent of mice with type 1 diabetes treated with a combination therapy of Lisofylline (LSF) (DiaKine Therapeutics) and INGAP Peptide (Kinexum Metabolics) went into complete remission and no longer needed insulin, LSF or INGAP Peptide in order to maintain normal blood sugar levels. Additionally, mice treated with this novel combination therapy required less insulin during the treatment regimen than the controls, according to results of a preclinical study presented at the prestigious Keystone Symposia on Beta Cell and Islet Biology.
